Trials / Completed
CompletedNCT01953523
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
Clinical Intervention Study: Adverse Events and Clinical Outcomes for the Deployment of Adipose Derived SVF (Rich in Adult Stem Cells and Growth Factors)for Select Orthopedic, Neurologic, Urologic, and Cardio-Pulmonary Conditions.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 3,000 (actual)
- Sponsor
- Elliot Lander · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Accepted
Summary
To evaluate for any adverse effects that may be related to the administration and reception of autologous adipose derived stromal vascular fraction (SVF). Secondarily, the study monitors the results of subjective and objective findings as it applies to the non-blinded deployment of autologous SVF for various inflammatory and/or degenerative conditions including select orthopedic, neurologic, urologic and cardio-pulmonary conditions. SVF deployments include intra-venous, intra-articular, and soft tissue injections.
Detailed description
SVF Stromal Vascular Fraction is obtained by lipoharvesting, procurement, and lipo-transfer as a same day operative procedure
Conditions
- Neurodegenerative Diseases
- Osteoarthritis
- Erectile Dysfunction
- Autoimmune Diseases
- Cardiomyopathies
- Emphysema
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Administration of autologous adipose derived SVF | Intra-venous, intra-articular, and soft tissue injection delivery of SVF |
Timeline
- Start date
- 2013-09-02
- Primary completion
- 2016-12-31
- Completion
- 2017-01-01
- First posted
- 2013-10-01
- Last updated
- 2018-09-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01953523. Inclusion in this directory is not an endorsement.